Roche and Basilea Sign a Research Collaboration to Evaluate Derazantinib + Tecentriq (atezolizumab) in Patients with Urothelial Cancer (UC)

 Roche and Basilea Sign a Research Collaboration to Evaluate Derazantinib + Tecentriq (atezolizumab) in Patients with Urothelial Cancer (UC)

Roche and Basilea Sign a Research Collaboration to Evaluate Derazantinib + Tecentriq (atezolizumab) in Patients with Urothelial Cancer (UC)

 Shots:

  •  Basilea to conduct the P-I/II biomarker-driven clinical trial with its expected initiation in H1’2019 and Roche to provide atezolizumab for the trial
  •  The focus of the agreement is for the onset of the trial assessing Basilea’s derazantinib in combination with Roche’s Tecentriq (atezolizumab) in patients with advanced (UC) and FGFR genomic defects
  •  Derazantinib (BAL087, formerly ARQ 087) is a panFGFR kinase inhibitor, in-licensed from ArQule in Aprl, 2018 and has received ODD from the US and EU for intrahepatic cholangiocarcinoma (iCCA). Tecentriq (atezolizumab) is a mAb inhibiting PD-L1 while blocking its interaction with PD-1 and B7.1 receptors

Click here  to read full press release/ article | Ref:  Basilea | Image: ArQule

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post